How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about belantamab mafodotin, pomalidomide and dexamethasone

Marketing authorisation indication

2.1

Belantamab mafodotin (BlenRep, GlaxoSmithKline) is indicated 'in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who have had at least one prior therapy including lenalidomide'.

Price

2.3

The list price for belantamab mafodotin is £16,848 per 100‑mg vial and £11,784 per 70‑mg vial (excluding VAT, company correspondence). The list price for pomalidomide is £7,995.60 per 21-pack of 1‑mg, 2‑mg, 3‑mg or 4‑mg tablets (excluding VAT; BNF online accessed June 2025).

2.4

GlaxoSmithKline has a commercial arrangement, which would have applied if belantamab mafodotin had been recommended.

2.5

There are nationally available price reductions for pomalidomide with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.